Skip to main content

Genprex, Inc.

corporate_fare Company Profile

Genprex, Inc.

GNPX·NASDAQ·Life Sciences·CIK 0001595248

We are a clinical stage gene therapy company focused on developing gene-based therapies for large patient populations with unmet medical needs. Our oncology platform uses our systemic, non-viral ONCOPREX® Delivery System, which employs lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. This product is administered intravenously and is taken up by tumor cells, which then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology for Type 1 diabetes aims to transform alpha cells in the pancreas into functional beta-like cells capable of producing insulin, potentially distinct enough from beta cells to evade the immune system. For Type 2 diabetes, our technology is believed to replenish and rejuvenate exhausted insulin-producing beta cells. Our lead oncology drug candidate, REQORSA® Gene Therapy (quaratusugene ozeplasmid), formerly GPX-001, is being developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). REQORSA has multimodal effects on cancer cells, harming their metabolism and reducing growth. Its mechanism of action decreases tumor glucose metabolism, interrupts cell signaling pathways causing cancer cell replication and proliferation, re-establishes programmed cell death (apoptosis) in cancer cells, and increases the immune response against them. Preclinical studies indicate REQORSA is complementary with targeted drugs and immunotherapies. Our strategy is to develop REQORSA in combination with currently approved therapies for NSCLC, SCLC, and potentially other cancers.

Genprex, Inc. (NASDAQ:GNPX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for GNPX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for GNPX spans 10-Q, 8-K, S-3, DEF 14A.

Recent high-impact activity:

  • Genprex Q3 10-Q: Going Concern Reiterated Despite $15.3M Cash After $18.7M ATM Raise
  • Genprex 10-Q: Persistent Material Weaknesses, Going Concern Reiterated, and New Nasdaq MVLS Delisting Risk
  • Genprex Taps Roche Diagnostics to Validate TROP2 Biomarker for NSCLC Trials
  • Genprex Secures Nasdaq Exception to Regain Compliance, Must Maintain $1.00 Bid Price Through December 7
  • Genprex Sets 1:22 Reverse Split Effective July 16 to Fight Nasdaq Delisting

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$16.23M
Op. Cash Flow
-$15.31M
Operating Income
-$15.52M
Cash & Equivalents
$7.83M
Debt / Equity
0.00×
Shares Outstanding
3.29M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010346

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 123,259 shares in GNPX as of the October 30, 2026 settlement, a 1.3% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 31.7% of GNPX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)123,259 shares as of October 30, 2026
Change vs prior period▼ 1.3%
Days to cover1.00 at avg daily volume of 170,473
Daily short volume (FINRA facilities)31.7% of 53,765 shares on November 20, 2026
5-day average short volume36.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for GNPX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.

1 shelf registrationreverse split

New Universal Shelf Registration · Replaces and Expands Prior Shelf

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with G →
$1.45
52-week range · as of 2026-11-13 $1.45 – $103.16
Market cap
$1.94M
Volume
93.7K (0.6× avg)
3-mo avg 158.4K
Live data · 2026-11-22 12:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GNPX - Latest Insights

GNPX
Nov 13, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.45 info
Change: -$0.630 (-30%) info
Market Cap: $1.935M info
GNPX
Aug 14, 2026, 9:27 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.00
Real-time Price: $1.45 info
Change: -$3.55 (-71%) info
Market Cap: $1.935M info
GNPX
Aug 03, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.65
Real-time Price: $1.45 info
Change: -$5.20 (-78%) info
Market Cap: $1.935M info
GNPX
Jul 30, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.50
Real-time Price: $1.45 info
Change: -$5.05 (-78%) info
Market Cap: $1.935M info
GNPX
Jul 14, 2026, 9:23 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.540
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Jun 22, 2026, 9:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.620
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Jun 18, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.582401
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Jun 12, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.645201
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Jun 12, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.6438
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Jun 05, 2026, 5:01 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.650
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
May 26, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.823511
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
May 13, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.8511
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Apr 30, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.9096
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Apr 30, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.920
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Apr 29, 2026, 4:47 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.8801
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Apr 28, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.938
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Apr 21, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.22
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Apr 17, 2026, 4:34 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.73
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
GNPX
Mar 18, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.04
Real-time Price: $1.45 info
Change: Reverse Stock Split info
Market Cap: $1.935M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets